A Non-interventional, Multi Center, Prospective Observational Study to Evaluate the Effect of Improving Systolic Blood Pressure and Low-density Lipoprotein Cholesterol Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab. in Patients With Essential Hypertension and Dyslipidemia.

The purpose of this study is to evaluate the effectiveness of Olostar Tablet on blood pressure and lipid profiles, obtain safety-related information for subgroups that failed to participate in the clinical trials, and to evaluate variables that affect treatment effectiveness.

Start Date20 Jun 2022

Sponsor / Collaborator

Daewoong Pharmaceutical Co., Ltd.

NCT02561884

/ Unknown statusPhase 1

A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study on a Olostar Tab Versus Two Co-administered Reference Products Olmesartan Medoxomil and Rosuvastatin Calcium in Healthy Volunteers

To demonstrate the bioequivalence of a Olostar Tab versus two co-administered reference IMPs Olmetec and Crestor.

Start Date01 Oct 2015

Sponsor / Collaborator

Daewoong Pharmaceutical Co., Ltd.

NCT01764295

/ CompletedPhase 3

Multi-institutional, Randomized, Double-Blind, Placebo-Control, Factorial Design, 4-arms, 8 Week Administration, Phase 3 Clinical Study for Patients With Hypertension Associated With Dyslipidemia

The purpose of this study is to evaluate the efficacy and safety of DWJ1276

Start Date01 Sep 2012

Sponsor / Collaborator

Daewoong Pharmaceutical Co., Ltd.

100 Clinical Results associated with Olmesartan Medoxomil/Rosuvastatin Calcium

100 Translational Medicine associated with Olmesartan Medoxomil/Rosuvastatin Calcium

100 Patents (Medical) associated with Olmesartan Medoxomil/Rosuvastatin Calcium

Literatures (Medical) associated with Olmesartan Medoxomil/Rosuvastatin Calcium

Drug design, development and therapyQ3 · MEDICINE

Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong)

Q3 · MEDICINE

ArticleOA

Author: Lee, Sang-Chol ; Shim, Wan-Joo ; Shin, Joon-Han ; Hyon, Min-Su ; Kang, Woong-Chol ; Kim, Young-Hak ; Kim, Hyo-Soo ; Jeong, Jin-Ok ; Nam, Chang-Wook ; Park, Jin-Sun ; Ahn, Youngkeun ; Park, Tae-Ho ; Choi, Dong-Hoon ; Hong, Taek-Jong ; Seo, Hong-Seog ; Kim, Sang-Hyun ; Baek, Sang-Hong

The pill burden of patients with hypertension and dyslipidemia can result in poor medication compliance. This study aimed to evaluate the efficacy and safety of fixed-dose combination (FDC) therapy with olmesartan medoxomil (40 mg) and rosuvastatin (20 mg) in Korean patients with mild to moderate hypertension and dyslipidemia. This multicenter, randomized, double-blind, factorial-design study included patients aged ≥20 years with mild to moderate essential hypertension and dyslipidemia. Patients were randomly assigned to receive FDC therapy (40 mg olmesartan medoxomil, 20 mg rosuvastatin), 40 mg olmesartan medoxomil, 20 mg rosuvastatin, or a placebo. The percentage change from baseline in low-density lipoprotein cholesterol levels was compared between FDC therapy and olmesartan medoxomil, and the change from baseline in diastolic blood pressure was compared between FDC therapy and rosuvastatin 8 weeks after treatment. A total of 162 patients were included. The least square mean percentage change (standard error) from baseline in low-density lipoprotein cholesterol levels 8 weeks after treatment was significantly greater in the FDC than in the olmesartan medoxomil group (-52.3% [2.8%] vs -0.6% [3.5%], P<0.0001), and the difference was -51.7% (4.1%) (95% confidence interval: -59.8% to -43.6%). The least square mean change (standard error) from baseline in diastolic blood pressure 8 weeks after treatment was significantly greater in the FDC group than in the rosuvastatin group (-10.4 [1.2] mmHg vs 0.1 [1.6] mmHg, P<0.0001), and the difference was -10.5 (1.8) mmHg (95% confidence interval: -14.1 to -6.9 mmHg). There were 50 adverse events in 41 patients (22.7%) and eight adverse drug reactions in five patients (2.8%). The study found that FDC therapy with olmesartan medoxomil and rosuvastatin is an effective, safe treatment for patients with hypertension and dyslipidemia. This combination may improve medication compliance in patients with a large pill burden.

04 Feb 2025·Microbiology Spectrum

Virulence profile of carbapenem-resistant Klebsiella pneumoniae strains by an in vivo model of Galleria mellonella

Article

Author: Visedo, Andrés ; Truglio, Mauro ; Pimpinelli, Fulvia ; Díaz-Navarro, Marta ; Hafian, Rama ; Sivori, Francesca ; Guembe, María ; De Maio, Flavio ; Di Domenico, Enea Gino ; Cavallo, Ilaria

ABSTRACT:

Klebsiella pneumoniae is a significant healthcare-associated pathogen, notable for its diverse virulence and antibiotic resistance profiles. This study aimed to characterize the genotypic and phenotypic diversity of K. pneumoniae isolates and evaluate their virulence using the Galleria mellonella model. Biomass production, metabolic activity, capsule formation, and siderophore production were assessed in 27 K . pneumoniae isolates from hospital-associated infections. Lethality curves were generated using the G. mellonella model, with survival monitored hourly from 16 to 48 hours. The most common sequence types (ST) identified were the high-risk clones ST307 ( N = 10), ST512 ( N = 8), ST101 ( N = 7), and ST661 ( N = 2). These STs were associated with distinct K-locus, including KL102, KL107, KL17, and KL39. Most isolates belonged to the O2afg locus ( N = 18), with the K. pneumoniae carbapenemase genotype detected in 96.3% of strains. None of the isolates were classified as hypervirulent. Phenotypically, ST661 exhibited the highest biomass production despite showing similar metabolic activity to other STs. A positive correlation was observed between biomass and siderophore production, while capsule production was inversely correlated with biomass. In the G. mellonella model, ST661 demonstrated the highest virulence, resulting in 100% mortality by 48 hours, compared to survival rates of 21.4% for ST101, 38.0% for ST307, and 31.2% for ST512. These findings underscore the pathogenic potential of ST661 isolates with enhanced biofilm production. The G. mellonella model may serve as an effective in vivo system for evaluating the virulence of emerging K. pneumoniae lineages.

IMPORTANCE:

We demonstrate that the Galleria mellonella model is a useful tool to analyze the virulence of carbapenem-resistant Klebsiella pneumoniae strains. Our findings highlight the pathogenicity of carbapenem-resistant K pneumoniae isolates, particularly the role of the ST661 that, despite being a rare lineage, harbors the blaVIM gene and is associated with high biofilm production and the highest mortality rates.

News (Medical) associated with Olmesartan Medoxomil/Rosuvastatin Calcium

01 Nov 2018

·www.biospace.com

SemaThera Board Names Garth Cumberlidge as President & CEO

Nov. 1, 2018 11:00 UTC MONTREAL--(BUSINESS WIRE)-- SemaThera Inc., announces today that its board of directors has appointed Garth Cumberlidge as President and Chief Executive Officer. Dr. Cumberlidge was also elected to the board of directors of SemaThera. He will lead the company’s development programs in diabetic macular edema and other degenerative retinopathies. Its lead compound, ST-102, is a bispecific recombinant protein trap, binding both VEGF and SEMA3A. “AmorChem is proud to welcome Garth Cumberlidge to the SemaThera team. Since its creation, the Company has generated very strong preclinical data and has already secured Senju Pharmaceutical Co., Ltd. as development partner in Japan and China. Garth’s extensive background in ophthalmology drug development, fundraising expertise and experience in nurturing early-stage assets is a perfect match for SemaThera’s needs. Moreover, Maxime Ranger, general partner at AmorChem, who was interim CEO of SemaThera, will continue to serve as Chairman adding his extensive early-stage development expertise to the company,” said Elizabeth Douville, co-founder and managing partner at AmorChem. “I am excited to have been given the opportunity to lead SemaThera and am extremely impressed with the quality of the decade-long scientific research work that forms the foundation of the company,” said Garth Cumberlidge. “Professor Mike (Przemyslaw) Sapieha and his co-workers have made some very significant discoveries that have led to the understanding of the function of semaphorins in general and semaphorin 3A in particular in both ocular and systemic pathologies and we are very fortunate to be able to continue to benefit from Mike’s scientific guidance, as Chief Scientific Officer, as we take the first lead compound into clinical studies.” ABOUT SEMATHERA INC SemaThera ( ) is a Montreal-based biotech company focused on the development of novel anti-SEMA3A therapies for the treatment of several retinopathies, including diabetic macular edema and wet age-related macular degeneration. SemaThera holds exclusive rights to various SEMA3A based technologies, where semaphorin 3A is involved in neo-angiogenesis, senescence and neuronal regeneration. Such technologies may also become future therapies in cancer and neurodegenerative diseases.

100 Deals associated with Olmesartan Medoxomil/Rosuvastatin Calcium

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	C09D	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dyslipidemias	KR	Daewoong Pharmaceutical Co., Ltd.	10 Jul 2013
Hypertension	KR	Daewoong Pharmaceutical Co., Ltd.	10 Jul 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis